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Abstract—The Unified Parkinson’s Disease Rating Scale 
(UPDRS) is a widely applied index of disease severity. Our 
objective was to assess the utility of UPDRS for predicting 
peak aerobic capacity (VO2 peak) and ambulatory function. 
Participants (n = 70) underwent evaluation for UPDRS (Total 
and Motor ratings), VO2 peak, 6-minute walk distance (6MW), 
and 30-foot self-selected walking speed (SSWS). Using regres-
sion, we determined the extent to which the Total and Motor 
UPDRS scores predicted each functional capacity measure 
after adjusting for age and sex. We also tested whether adding 
the Hoehn and Yahr scale (H-Y) to the model changed predic-
tive power of the UPDRS. Adjusted for age and sex, both the 
Total UPDRS and Motor UPDRS subscale failed to predict 
VO2 peak. The Total UPDRS did weakly predict 6MW and 
SSWS (both p < 0.05), but the Motor UPDRS subscale did not 
predict these ambulatory function tests. After adding H-Y to 
the model, Total UPDRS was no longer an independent predic-
tor of 6MW but remained a predictor of SSWS. We conclude 
that Total and Motor UPDRS rating scales do not predict VO2
peak, but that a weak relationship exists between Total UPDRS 
and measures of ambulatory function.
Key words: 6-minute walk distance, ambulatory function, dis-
ease severity, endurance, motor function, Parkinson disease, 
self-selected walking speed, UPDRS, VO2 peak, walking.
INTRODUCTION
The Unified Parkinson’s Disease Rating Scale 
(UPDRS) is the most widely applied rating instrument 
for Parkinson disease (PD) [1–2]. The Total UPDRS 
score includes 31 items contributing to three subscales: 
(I) Mentation, Behavior, and Mood; (II) Activities of 
Daily Living; and (III) Motor Examination [2]. The 
UPDRS does not assess general cardiovascular fitness 
and provides only limited information on functional per-
formance relevant to daily activities, although this infor-
mation would facilitate clinical decision-making. 
Therefore, there is value in determining the predictive 
power of the UPDRS for more time-consuming and 
resource-intensive measures such as peak aerobic capac-
ity (VO2 peak) and ambulatory function.
The UPDRS includes an examination of extrapyra-
midal motor function and has been shown to predict 
physical performance measures with a strong balance 
component, such as Berg Balance and the functional 
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reach tests [3–4]. Further, previous studies have shown 
that the UPDRS associates with daily function [3–5] and 
is sensitive to change over time [1] and across rehabilita-
tion interventions [5–6]. However, uncertainty remains 
regarding the extent to which UPDRS predicts important 
aspects of function associated with ambulatory function, 
considering that prior investigations have failed to 
observe associations between UPDRS and 6-minute walk 
distance (6MW) [7] or between UPRDS and submaximal 
oxygen consumption during treadmill walking [8]. 
Importantly, no studies have evaluated whether the 
UPDRS predicts VO2 peak, a gold standard objective 
physical performance measure of cardiovascular fitness. 
Hence, the current study sought to enhance understand-
ing about whether UPDRS predicts VO2 peak and ambu-
latory function by examining the relationship of Total 
and Motor UPDRS with VO2 peak, 6MW, and floor 
walking speed. Based on limited prior work, we hypothe-
sized that UPDRS would fall short of predicting VO2
peak and ambulatory function, both of which have an 
endurance requirement.
METHODS
Subjects
Recruits for this cross-sectional study came from the 
University of Maryland Parkinson’s Disease Center and 
the Baltimore Department of Veterans Affairs (VA) Med-
ical Center. All had volunteered to participate in a ran-
domized exercise intervention trial designed specifically 
for PD patients. Entry criteria for this study have been 
described previously in Katzel et al. [9] and are included 
in the Appendix (available online only).
All tests of VO2 peak and ambulatory function were 
conducted on separate days to avoid the confounding 
effects of fatigue. The tests were done in the same order 
for all subjects. The treadmill VO2 peak test was done 1 wk
after assessment of ambulatory function (self-selected 
walking speed [SSWS] and 6MW). Further, all study 
evaluations (rating scales, VO2 peak, and ambulatory 
function testing) were conducted soon after medication 
intake (<3 h) while the subjects were “on.” When 
required, subjects took an additional dose to maintain the 
“on” state during evaluation.
Unified Parkinson’s Disease Rating Scale Evaluation
The UPDRS scale was scored by a single neurologist 
to avoid the confounding effects of interrater variability. 
The evaluator is a board-certified neurologist and spe-
cialist in PD who is certified in the administration of the 
UPDRS. The UPDRS Total score was computed as the 
sum of UPDRS subscales I, II, and III.
Peak Aerobic Capacity
Treadmill testing was always conducted during the 
early afternoon hours when subjects were “on” soon after 
taking medication. Exercise tests were terminated accord-
ing to American College of Sports Medicine guidelines 
[10]. Gait belts and other safety precautions protected 
against falls resulting from loss of balance. There were 
no falls during the treadmill VO2 peak tests or assess-
ments of ambulatory function. Subjects were instructed 
to use as little handrail support as possible during the 
treadmill tests.
Both the treadmill testing (VO2 peak) and over-
ground ambulatory function testing (SSWS and 6MW) 
protocols have been previously described for this study 
population in articles by Katzel et al. [9,11], and those 
descriptions are provided in the Appendix (available 
online only).
Statistical Methods
Separate multiple regressions were used to evaluate 
UPDRS as a predictor of each of the three performance 
measures (VO2 peak, SSWS, and 6MW). For each out-
come, a separate analysis for both Total UPDRS and 
Motor UPDRS was run. All analyses were originally 
adjusted for age and sex. The models were then rerun 
after adding a simpler measure of disease progression 
(Hoehn and Yahr scale [H-Y]) to determine whether the 
predictive strength of the UPDRS remained. H-Y is a 
clinical staging instrument that is even more widely uti-
lized than UPDRS. Therefore, addition of H-Y to the 
model answers an important question related to whether 
UPDRS adds anything to the functional information 
obtained from the more routine H-Y scale. Probability 
values 0.05 were considered significant.
RESULTS
Subjects
A total of 70 participants were studied. Fewer obser-
vations (n = 64) were available for the 6MW analysis 
because of missed tests. Participants were predominantly 
Caucasian (90%) and male (71%) and had a mean age of 
65 yr (Table 1). The mean H-Y score of 2.2 was indicative1271
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of a mild to moderately impaired population of PD par-
ticipants. The means for SSWS, 6MW, and VO2 peak 
were also consistent with mild to moderate disability. The 
diversity of disability is captured by the range of scores 
for the total UPDRS (15–89) and H-Y (1.5–3.0) (Table 1).
Unified Parkinson’s Disease Rating Scale as Predictor 
of Peak Aerobic Capacity
Neither Total UPDRS (0.024 ± 0.034, β ± standard 
error [SE], p = 0.492) nor Motor UPDRS (0.038 ± 
0.048, β ± SE, p = 0.429) were significant predictors of 
VO2 peak after correcting for age and sex (Table 2). Both 
age (0.190 ± 0.042, p < 0.001) and sex (3.821 ± 0.986, 
p < 0.001) were independent predictors of VO2 peak. For 
each year of age, VO2 dropped by about 0.2 mL/kg/min, 
and female participants with PD had VO2 peak measure-
ments that were on average 3.8 mL/kg/min lower than 
males. Neither H-Y alone nor H-Y combined with the 
UPDRS measures was a significant predictor of VO2 peak.
Unified Parkinson’s Disease Scale as Predictor of 
Ambulatory Function
When UPDRS ratings were evaluated for prediction 
of ambulatory 
Variable Mean ± SD Range
Age (yr) (n = 70) 65 ± 11 42–86
Race (White: Black: Hispanic) 63:5:2 —
Hoehn and Yahr Score 2.2 ± 0.4 1.5–3.0
UPDRS Total Score 47.1 ± 12.8 15–89
UPDRS Motor Score 32.3 ± 9.6 11–59
Body Mass Index (kg/m2) 28.4 ± 5.0 18.0–41.6
Self-Selected Walking Speed (m/s) 1.1 ± 0.2 0.5–1.7
6-Minute Walk Distance (m) (n = 64) 414 ± 102 122–654
VO2 Peak (mL/kg/min) 21.4 ± 4.2 12.8–32.0
function (6MW and SSWS), 
Relationship between Unified Parkinson’s Disease Rating Scale (UPDRS) (Total and Motor scales) and peak aerobic capacity (VO2 peak) with 
and without (bold) Hoehn-Yahr scale entered in model.
Outcome N R2 Effect Intercept Age (yr) Sex (F vs M)
Hoehn-Yahr 
(Low vs High)
UPDRS
Total Motor
VO2 peak (mL/kg/min) 70 0.311 β 35.995 0.190 3.821 — –0.024 —
SE 3.187 0.042 0.986 — 0.034 —
p 0.000 0.000 0.000 — 0.492 —
70 0.313 β 36.619 0.189 3.955 0.461 0.028 —
SE 3.583 0.042 1.050 1.179 0.036 —
p 0.000 0.000 0.000 0.697 0.439 —
70 0.313 β 36.015 0.187 3.966 — — –0.038
SE 3.113 0.042 1.014 — — 0.048
p 0.000 0.000 0.000 — — 0.429
70 0.314 β 36.400 0.187 4.071 0.338 — 0.041
SE 3.389 0.042 1.080 1.131 — 0.049
p 0.000 0.000 0.000 0.766 — 0.408
70 0.307 β 35.119 0.191 3.802 0.148 — —
SE 3.013 0.042 1.028 1.105 — —
p 0.000 0.000 0.000 0.894 — —
only Total 
Table 1.
Participant characteristics.
SD = standard deviation, UPDRS = Unified Parkinson’s Disease Rating Scale, VO2 peak = peak aerobic capacity.
Table 2.
F = female, M = male, SE = standard error of mean.1272
JRRD, Volume 49, Number 8, 2012
UPDRS was an independent predictor for 6MW (2.122 ±
0.884, β ± SE, p = 0.020) and SSWS (0.005 ± 0.002, p = 
0.008) after adjusting for age and sex (Table 3). Total 
UPDRS, age, and sex explained 16 percent of the vari-
ance in 6MW and 24 percent of the variance in SSWS, 
indicating a weak but statistically significant relationship 
(Figure). Conversely, Motor UPDRS was not a signifi-
cant predictor of either SSWS or 6MW, adjusting for age 
and sex. For both ambulatory function tests, age but not 
sex was a significant independent predictor. When H-Y 
score was added to the model, the Total UPDRS was no 
longer a significant independent predictor of 6MW, but 
the independent relationship between Total UPDRS and 
SSWS was retained (p = 0.046) (Table 3). Thus, the inde-
pendent predictive strength of Total UPDRS for longer 
distance ambulatory function was compromised when a 
simpler global measure of disease severity was added.
H-Y evaluated alone without UPDRS in the model did 
predict a significant portion of the variance for both 
am
Outcome N R2 Effect Intercept Age (yr) Sex (F vs M)
Hoehn-Yahr 
(Low vs High)
UPDRS
Total Motor
6-Minute 64 0.163 β 676.069 –2.493 –21.565 — –2.122 —
Walk (m) SE 83.460 1.112 26.222 — 0.884 —
p 0.000 0.029 0.414 — 0.020 —
64 0.387 β 482.189 –2.510 27.150 130.982 –0.442 —
SE 83.193 0.960 24.927 28.163 0.844 —
p 0.000 0.011 0.280 0.000 0.603 —
64 0.088 β 609.261 –2.601 –18.307 — — –0.821
SE 85.995 1.167 28.533 — — 1.328
p 0.000 0.030 0.524 — — 0.539
64 0.391 β 426.279 –2.642 39.269 143.462 — 0.937
SE 78.474 0.962 25.794 26.458 — 1.141
p 0.000 0.008 0.133 0.000 — 0.415
64 0.384 β 457.681 –2.545 30.990 137.289 — —
SE 68.340 0.952 23.678 25.299 — —
p 0.000 0.010 0.196 0.000 — —
Self-Selected 
Walking Speed 
(m/s)
70 0.237 β 1.890 –0.008 –0.104 — –0.005 —
SE 0.183 0.002 0.057 — 0.002 —
p 0.000 0.001 0.071 — 0.008 —
70 0.270 β 1.738 –0.008 –0.071 0.113 –0.004 —
SE 0.201 0.002 0.059 0.066 0.002 —
p 0.000 0.001 0.232 0.092 0.046 —
70 0.185 β 1.791 –0.008 –0.116 — –0.005
SE 0.185 0.002 0.060 — — 0.003
p 0.000 0.002 0.058 — — 0.095
70 0.242 β 1.629 –0.008 –0.072 0.143 — –0.004
SE 0.194 0.002 0.062 0.065 — 0.003
p 0.000 0.002 0.249 0.031 — 0.212
70 0.223 β 1.518 –0.008 –0.049 0.159 — —
SE 0.174 0.002 0.059 0.064 — —
p 0.000 0.001 0.415 0.015 — —
bulatory function measures (Table 3).
Table 3.
Relationship between Unified Parkinson’s Disease Rating Scale (UPDRS) and function accessed by 6-Minute Walk Distance and Self-Selected 
Walking Speed with and without (bold) Hoehn-Yahr entered in model.
F = female, M = male, SE = standard error of mean.1273
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DISCUSSION
Our results show that neither the Total nor Motor 
UPDRS predicts VO2 peak in mild to moderate PD. Total 
UPDRS but not Motor UPDRS was found to weakly pre-
dict ambulatory function. These findings extend the work 
of previous investigations on the clinical and functional 
significance of UPDRS ratings [3,12–13].
The UPDRS is the most common instrument used to 
track PD severity and is widely considered the gold stan-
dard for evaluation of PD in both clinical and research 
settings [1–2]. The UPDRS has attained this status based 
on both its reliability [14–16] and sensitivity to change 
over time [6,17]. Nonetheless, the relationship between 
UPDRS ratings and progression of disability is not fully 
understood [18–19]. The ability of the UPDRS to predict 
performance on quantitative tests of physical function 
has also not been fully established [3]. Our study shows 
that UPDRS is not associated with VO2 peak, a perfor-
mance measure relevant to cardiovascular and metabolic 
health as well as general functional capacity. Items in the 
UPDRS focus predominantly on the motor features of PD 
including bradykinesia, rigidity, and tremor [1–2]. Non-
motor features of PD such as cognitive impairment, auto-
nomic dysfunction, depression, and sleep disorders have 
received increasing attention in recent years [20–21] and 
may contribute to variations in functional status. Interest-
ingly, none of the items on the UPDRS assess the level of 
physical activity or endurance.
The UPDRS has been shown to predict physical per-
formance measures with a strong balance component. For 
example, Tanji et al. compared ratings on the Berg Bal-
ance Scale and Functional Reach tests with Total and 
Motor UPDRS in 79 participants with a range of PD 
severity [3]. The results showed relatively strong correla-
tions between UPDRS ratings and these measures of 
physical performance. Similarly, Brusse et al. found asso-
ciations between the UPDRS and tests of balance, but 
failed to observe associations with ambulatory function 
[4]. They concluded that the single item of gait assess-
ment in the Motor UPDRS (item 29) is inadequate to 
reflect walking performance [4]. This point may also be 
relevant to the weak performance of the UPDRS in pre-
dicting the ambulatory function and VO2 peak measures 
in this study. Hence, previous studies indicate that the 
UPDRS may be a decent predictor of short physical per-
formance measures with a strong balance component, but 
our results and others cast doubt on its utility for predicting
ambulatory f
Figure. 
Scatter plots depicting relationship between total Unified Par-
kinson’s Disease Rating Scale (UPDRS) and (a) 6-minute walk 
or (b) self-selected walking speed (SSWS). Modest but signifi-
cant relationship disappeared after adding Hoehn and Yahr to 
model for (a) but not (b).
unction and VO2 peak performance, which 
requires sustained effort and a degree of endurance. 
Although studies have shown that the UPDRS is correlated
with community ambulation patterns as measured by step 
activity monitoring [5], the distance walked over the course
of a day in the community is a different aspect of func-
tion than measures of ambulatory function and VO2 peak 
obtained during formal laboratory testing. This is based on 
the higher levels of effort required for the laboratory tests. 
Both our findings and those of Falvo and Earhart [7] 1274
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demonstrate that the UPDRS is not an independent pre-
dictor of 6MW when age and H-Y are added to the 
regression model.
The absence of an association between UPDRS and 
VO2 peak observed in this study is partially supported by 
previous studies measuring VO2 in PD. Canning et al. 
showed that VO2 peak during cycle ergometry was not 
related to disease severity as assessed by H-Y staging 
[22]. Additionally, Christiansen et al. measured submaxi-
mal VO2 during treadmill walking in PD (2.3 mph, 0 
grade) and found that VO2 was not correlated with Total 
UPDRS [8]. In combination with our results, it is reason-
able to conclude that, in patients with mild to moderate 
PD, the UPDRS does not reflect either peak or submaxi-
mal aerobic performance.
Limitations of this study include the failure to study 
the full range of PD severity. Because we studied subjects 
with mild to moderate impairment (H-Y 1.5–3 while 
“on,” mean 2.2 ± 0.4), our results may not be generaliz-
able to the full spectrum of disease severity. Floor effects 
may limit sensitivity of the UPDRS in milder stages of 
the disease [1]. In addition to studying a broader range of 
disease severity, future studies should compare UPDRS 
with a larger battery of objective functional outcome 
tests. In this study, the majority of patients (57%) did not 
experience motor fluctuations, while 43 percent had fluc-
tuations. There is no way to completely eliminate poten-
tial effects from varying medication levels. However, we 
attempted to proactively address this by performing exer-
cise and study evaluations while the subjects were within 
3 h of antiparkinsonian medication administration. If par-
ticipants perceived that their medications were wearing 
off, our protocol permitted administration of an addi-
tional dose of antiparkinsonian medication, but this was 
not necessary during the study.
CONCLUSIONS
To summarize, the results shed additional light on the 
functional and clinical relevance of the UPDRS. The data 
show that PD severity assessed by the UPDRS Motor 
Examination subscale does not predict VO2 peak or 
ambulatory function (6MW, SSWS). Further, Total 
UPDRS does not predict VO2 peak but does indepen-
dently predict SSWS, albeit modestly. Although there 
was a weak association between 6MW and Total UPDRS, 
the relationship disappeared after adding H-Y to the 
model. Lack of association with VO2 peak may partly be 
a function of the underemphasis of UPDRS items on 
ambulatory function and associated elements of endur-
ance. The UPDRS will continue to be widely used in 
assessing disease progression and the effectiveness of 
neuroprotective agents and for therapeutic decision-making
by clinicians [2,13]. Hence, increased understanding about
the scale’s limitations in predicting results on ambulatory 
function and VO2 peak tests is important. Future attempts 
at revising the UPDRS scale should consider components 
related to sustained activity and endurance.
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